High performing – unique – clinically proven
Visco booster with dual effect based on hyaluronic acid combined with niacinamide.
Dual effect
1 Hummer, C.D., Angst, F., Ngai, W. et al. High molecular weight Intraarticular hyaluronic acid for the treatment of knee osteoarthritis: a network meta-analysis. BMC Musculoskelet Disord 21, 702 (2020). https://doi.org/10.1186/s12891-020-03729-w
2 Ogata S, Takeuchi M, Teradaira S, Yamamoto N, Iwata K, Okumura K, Taguchi H. Radical scavenging activities of niacin related compounds. Biosci Biotechnol Biochem. 2002 Mar;66(3):641-5. doi: 10.1271/bbb.66.641. PMID: 12005062
3 Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res. 1996 Jul; 45(7):330-4. doi: 10.1007/BF02252945. PMID: 8841834
4 Atlantic Bone Screen, assigned by ALBOMED GmbH. In-vitro evaluation of the anti-hypertrophic effect of 1 product on rat chondrocytes. 2019
INNORYOS®
The first visco booster
INNORYOS® combines sodium hyaluronate and niacinamide in an advanced viscosupplement formulation designed to support joint lubrication and shock absorption.
- Helps restore the viscoelastic properties of synovial fluid affected by osteoarthritis
- Enhances the stability of the hyaluronate-based hydrogel
- Demonstrates enhanced resistance to oxidative degradation
- Promotes intermolecular interactions within the hyaluronate network, contributing to hydrogel stability
- Provides lubricating and shock-absorbing properties to support joint function
INNORYOS® combines enhanced hydrogel stability with the benefits of viscosupplementation for the symptomatic management of osteoarthritis.
Key facts of INNORYOS®:
- Well-targeted molecular weight
- Ultra pure hyaluronic acid (bio-fermented) plus niacinamide
- Clinical evidence confirmed
- For synovial joints
- Double sterile barrier system (by steam); suitable for OR use
- Shelf life: 42 month
- CE certified
Data table
Below you will find the specification of the INNORYOS® product line, including the color coding that helps to easily distinguish between the different concentrations.
|
Specification
|
INNORYOS®
|
||||||
|---|---|---|---|---|---|---|---|
|
Concentration
|
1.6% HA
1.5% Niacinamide |
1.6% HA
1.5% Niacinamide |
2.2% HA
1.5% Niacinamide |
2.5% HA
1.5% Niacinamide |
|||
|
Sodium hyaluronate (mg)
|
16
|
32
|
44
|
120
|
|||
|
Molecular weight* (MDa)
|
1.2-2.2
|
1.2-2.2
|
1.2-2.2
|
1.2-2.2
|
|||
|
Viscosity* (mPas)
|
70 000
|
70 000
|
370 000
|
600 000
|
|||
|
Volume (ml)
|
1.0
|
2.0
|
2.0
|
4.8
|
|||
|
Forms of therapy
|
1 to 5 injections
|
1 to 5 injections
|
1 to 5 injections
|
1 to 5 injections
|
|||
|
Storage (°C)
|
2–25
|
2–25
|
2–25
|
2–25
|
|||
* mean value after steam sterilization
News
Stay informed: keep yourself up-to-date with the latest news and developments.
ALBOMED at ESCRS 2026: Strengthening Partnerships and Creating New Opportunities
ALBOMED Supports Humanitarian Project in the Central African Republic
ESCRS CONGRESS 2026 – LONDON
INNORYOS® – Publication Summary
Headoffice
ALBOMED GmbH
Hildebrandstr. 11
90592 Schwarzenbruck | Germany
info@albomed.eu
+49 (0) 9183 95 69 82-0
Facility UNNA I | Logistic center
Otto-Brenner-Str. 7
59425 Unna | Germany
Facility UNNA II | Production
Isaac-Newton-Str. 7
59423 Unna | Germany